Changshan Pharmaceutical Holding's subsidiary 1.1 class new drug Albenatide starts phase III clinica

At present, the company has completed the relevant work of Phase II clinical research and preparation of Phase III clinical trial of Albenatide injection. According to the preliminary clinical trial results and clinical trial approval requirements of Albenatide injection, combined with the actual situation of the company, the company believes that it already has the conditions to start the phase III clinical trial and decides to start the phase III clinical trial.

Albenatide is a class 1.1 drug for the treatment of type II diabetes. It is a long-acting GLP-1 receptor agonist preparation that can be injected once a week, which greatly improves the patient's compliance with medication.

The company carried out the phase I clinical trial of Albenatide injection at the First Hospital of Jilin University, and the clinical trial of Albenatide injection phase II at 28 hospitals including Peking University People's Hospital. After the Phase II clinical trial of Albenatide Injection was completed on June 7, 2019, the company conducted subsequent statistical analysis and collation of relevant research data. Up to now, the company has completed the phase II clinical research related to Albenatide injection. The results of the phase II clinical trial of Albenatide injection showed that the main endpoint of the phase II clinical trial was reached.